Trial Profile
TACTI-002 (Two ACTive Immunotherapeutics): A Multicenter, Open Label, Phase II Study in Patients With Previously Untreated Unresectable or Metastatic Non-small Cell Lung Cancer (NSCLC), or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic Squamous Head and Neck Cancer (HNSCC) Receiving the Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) in Combination With Pembrolizumab (PD-1 Antagonist)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2023
Price :
$35
*
At a glance
- Drugs Eftilagimod alpha (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Non-small cell lung cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms Keynote-798; KEYNOTE-PN798; TACTI-002
- Sponsors Immutep Limited
- 03 Nov 2023 According to an Immutep Limited media release, new biomarker data from this trial were presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2023.
- 03 Nov 2023 New biomarker data presented in an Immutep Limited Media Release.
- 31 Oct 2023 Overall survival results of eftilagimod alpha + pembrolizumab in patients with 1st line non-small cell lung cancer patients, presented in an Immutep Limited Media Release.